BACKGROUND & AIMS: Gastrointestinal polyposis is a common clinical problem, yet there is no consensus on how to best manage patients with moderate-load polyposis. Identifying genetic features of this disorder could improve management and especially surveillance of these patients. We sought to determine the prevalence of hamartomatous polyposis-associated mutations in the susceptibility genes PTEN, BMPR1A, SMAD4, ENG, and STK11 in individuals with ≥5 gastrointestinal polyps, including at least 1 hamartomatous or hyperplastic/serrated polyp. METHODS: We performed a prospective, referral-based study of 603 patients (median age: 51 years; range, 2-89 years) enrolled from June 2006 through January 2012. Genomic DNA was extracted from peripheral lymphocytes and analyzed for specific mutations and large rearrangements in PTEN, BMPR1A, SMAD4, and STK11, as well as mutations in ENG. Recursive partitioning analysis was used to determine cutoffs for continuous variables. The prevalence of mutations was compared using Fisher's exact test. Logistic regression analyses were used to determine univariate and multivariate risk factors. RESULTS: Of 603 patients, 119 (20%) had a personal history of colorectal cancer and most (n = 461 [76%]) had <30 polyps. Seventy-seven patients (13%) were found to have polyposis-associated mutations, including 11 in ENG (1.8%), 13 in PTEN (2.2%), 13 in STK11 (2.2%), 20 in BMPR1A (3.3%), and 21 in SMAD4 (3.5%). Univariate clinical predictors for risk of having these mutations included age at presentation younger than 40 years (19% vs 10%; P = .008), a polyp burden of ≥30 (19% vs 11%; P = .014), and male sex (16% vs 10%; P = .03). Patients who had ≥1 ganglioneuroma (29% vs 2%; P < .001) or presented with polyps of ≥3 histologic types (20% vs 2%; P = .003) were more likely to have germline mutations in PTEN. CONCLUSIONS: Age younger than 40 years, male sex, and specific polyp histologies are significantly associated with risk of germline mutations in hamartomatous-polyposis associated genes. These associations could guide clinical decision making and further investigations.
BACKGROUND & AIMS:Gastrointestinal polyposis is a common clinical problem, yet there is no consensus on how to best manage patients with moderate-load polyposis. Identifying genetic features of this disorder could improve management and especially surveillance of these patients. We sought to determine the prevalence of hamartomatous polyposis-associated mutations in the susceptibility genes PTEN, BMPR1A, SMAD4, ENG, and STK11 in individuals with ≥5 gastrointestinal polyps, including at least 1 hamartomatous or hyperplastic/serrated polyp. METHODS: We performed a prospective, referral-based study of 603 patients (median age: 51 years; range, 2-89 years) enrolled from June 2006 through January 2012. Genomic DNA was extracted from peripheral lymphocytes and analyzed for specific mutations and large rearrangements in PTEN, BMPR1A, SMAD4, and STK11, as well as mutations in ENG. Recursive partitioning analysis was used to determine cutoffs for continuous variables. The prevalence of mutations was compared using Fisher's exact test. Logistic regression analyses were used to determine univariate and multivariate risk factors. RESULTS: Of 603 patients, 119 (20%) had a personal history of colorectal cancer and most (n = 461 [76%]) had <30 polyps. Seventy-seven patients (13%) were found to have polyposis-associated mutations, including 11 in ENG (1.8%), 13 in PTEN (2.2%), 13 in STK11 (2.2%), 20 in BMPR1A (3.3%), and 21 in SMAD4 (3.5%). Univariate clinical predictors for risk of having these mutations included age at presentation younger than 40 years (19% vs 10%; P = .008), a polyp burden of ≥30 (19% vs 11%; P = .014), and male sex (16% vs 10%; P = .03). Patients who had ≥1 ganglioneuroma (29% vs 2%; P < .001) or presented with polyps of ≥3 histologic types (20% vs 2%; P = .003) were more likely to have germline mutations in PTEN. CONCLUSIONS: Age younger than 40 years, male sex, and specific polyp histologies are significantly associated with risk of germline mutations in hamartomatous-polyposis associated genes. These associations could guide clinical decision making and further investigations.
Authors: S Roth; P Sistonen; R Salovaara; A Hemminki; A Loukola; M Johansson; E Avizienyte; K A Cleary; P Lynch; C I Amos; P Kristo; J P Mecklin; I Kellokumpu; H Järvinen; L A Aaltonen Journal: Genes Chromosomes Cancer Date: 1999-09 Impact factor: 5.006
Authors: Kevin Sweet; Joseph Willis; Xiao-Ping Zhou; Carol Gallione; Takeshi Sawada; Pia Alhopuro; Sok Kean Khoo; Attila Patocs; Cossette Martin; Scott Bridgeman; John Heinz; Robert Pilarski; Rainer Lehtonen; Thomas W Prior; Thierry Frebourg; Bin Tean Teh; Douglas A Marchuk; Lauri A Aaltonen; Charis Eng Journal: JAMA Date: 2005-11-16 Impact factor: 56.272
Authors: J G Park; H F Vasen; K J Park; P Peltomaki; M Ponz de Leon; M A Rodriguez-Bigas; J Lubinski; N E Beck; M L Bisgaard; M Miyaki; J T Wijnen; S Baba; H T Lynch Journal: Dis Colon Rectum Date: 1999-06 Impact factor: 4.585
Authors: M Nielsen; F J Hes; F M Nagengast; M M Weiss; E M Mathus-Vliegen; H Morreau; M H Breuning; J T Wijnen; C M J Tops; H F A Vasen Journal: Clin Genet Date: 2007-05 Impact factor: 4.438
Authors: Deborah W Neklason; Jeffery Stevens; Kenneth M Boucher; Richard A Kerber; Nori Matsunami; Jahn Barlow; Geraldine Mineau; Mark F Leppert; Randall W Burt Journal: Clin Gastroenterol Hepatol Date: 2007-12-11 Impact factor: 11.382
Authors: Rosemary E Teresi; Kevin M Zbuk; Marcus G Pezzolesi; Kristin A Waite; Charis Eng Journal: Am J Hum Genet Date: 2007-08-15 Impact factor: 11.025
Authors: Carlos J Gallego; Brian H Shirts; Caroline S Bennette; Greg Guzauskas; Laura M Amendola; Martha Horike-Pyne; Fuki M Hisama; Colin C Pritchard; William M Grady; Wylie Burke; Gail P Jarvik; David L Veenstra Journal: J Clin Oncol Date: 2015-05-04 Impact factor: 44.544
Authors: Raymond H Kim; Xiangling Wang; Andrew J Evans; Steven C Campbell; Jane K Nguyen; Kirsten M Farncombe; Charis Eng Journal: NPJ Genom Med Date: 2020-09-29 Impact factor: 8.617
Authors: Clara Esteban-Jurado; Pilar Garre; Maria Vila; Juan José Lozano; Anna Pristoupilova; Sergi Beltrán; Anna Abulí; Jenifer Muñoz; Francesc Balaguer; Teresa Ocaña; Antoni Castells; Josep M Piqué; Angel Carracedo; Clara Ruiz-Ponte; Xavier Bessa; Montserrat Andreu; Luis Bujanda; Trinidad Caldés; Sergi Castellví-Bel Journal: World J Gastroenterol Date: 2014-02-28 Impact factor: 5.742
Authors: Clara Esteban-Jurado; Maria Vila-Casadesús; Pilar Garre; Juan José Lozano; Anna Pristoupilova; Sergi Beltran; Jenifer Muñoz; Teresa Ocaña; Francesc Balaguer; Maria López-Cerón; Miriam Cuatrecasas; Sebastià Franch-Expósito; Josep M Piqué; Antoni Castells; Angel Carracedo; Clara Ruiz-Ponte; Anna Abulí; Xavier Bessa; Montserrat Andreu; Luis Bujanda; Trinidad Caldés; Sergi Castellví-Bel Journal: Genet Med Date: 2014-07-24 Impact factor: 8.822